فريق إنت عربي
- Texas-based medical robotics company XCath secured $30 million in a Series C funding round.
- The investment was co-led by UAE-headquartered Crescent Enterprises and Dr. Fred Moll.
- The new funding brings XCath’s total capital raised to $92 million
XCath, a Texas-based medical device company developing neuro-endovascular surgical robotics, has raised $30 million in a Series C funding round, bringing the total capital raised since its founding to $92 million.
The round was co-led by Crescent Enterprises, a UAE-headquartered diversified business group that already holds a stake in the company, along with Dr. Fred Moll, chairman of XCath’s board of directors.
Founded in 2017 as a spinout from the University of Texas’ Microsurgical Robotics Laboratory, XCath focuses on developing robotic systems designed to assist physicians in performing delicate procedures inside blood vessels.
The company’s technology targets neuro-endovascular interventions, a field that requires extremely precise navigation through complex vascular structures. Robotic assistance in these procedures could help improve surgical precision and reduce risks for patients.
The new funding is expected to support XCath’s continued research and development efforts as the company advances its robotic system toward clinical use and broader medical adoption.
